Why is SPARC falling/rising?

Recent Price Movement and Market Performance

SPARC’s stock price closed at ₹132.80 on 16 December, down by ₹3.50 or 2.57% from the previous session. This decline continues a five-day losing streak, during which the stock has fallen by 6.45%. The intraday low touched ₹132.20, marking a 3.01% drop within the trading day. Notably, the stock has underperformed its sector by 2.04% today and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

Investor participation has also waned, with delivery volumes on 15 December falling sharply by 61.27% compared to the five-day average, indicating reduced buying interest. Despite this, liquidity remains adequate for trades up to ₹0.86 crore based on 2% of the five-day average traded value, suggesting that while the stock is actively traded, investor conviction is lacking.

Long-Term Weakness and Financial Struggles

SPARC’s long-term fundamentals remain weak, as evidenced by its negative book value and poor growth metrics. Over the past five years, the company’s net sales have declined at an annual rate of 24.65%, while operating profit has contracted by 1.19% annually. This deterioration in core business performance has undermined investor confidence and contributed to the stock’s underperformance relative to benchmarks.

The company’s ability to service its debt is also concerning, with an average EBIT to interest ratio of -141.22, indicating that earnings before interest and tax are insufficient to cover interest expenses. This financial strain is further reflected in the latest quarterly results, which were notably weak.

Disappointing Quarterly Results and Profitability Concerns

In the quarter ending September 2025, SPARC reported a 6.73% decline in operating profit, marking the second consecutive quarter of negative results. The company’s net sales for the quarter were at a low ₹7.86 crore, while interest expenses surged to ₹7.52 crore, exacerbating profitability pressures. The latest six-month period saw a net loss (PAT) of ₹127.72 crore, worsening by 41.02% year-on-year.

Despite the stock generating a 34.6% rise in profits over the past year, the share price has fallen sharply by 42.39%, highlighting a disconnect between earnings and market valuation. This divergence suggests that investors remain cautious due to the company’s negative EBITDA and overall risk profile.

Comparative Underperformance and Market Sentiment

SPARC’s stock has consistently underperformed key market indices and sector benchmarks. Year-to-date, the stock is down 33.68%, while the Sensex has gained 8.37%. Over one year, the stock has declined by 42.39%, contrasting with a 3.59% rise in the Sensex. Even over three and five years, SPARC’s returns lag significantly behind the broader market, which has delivered gains of 38.05% and 81.46% respectively.

This sustained underperformance, combined with weak financial results and falling investor participation, has contributed to a negative market sentiment surrounding the stock. The dominance of promoter shareholding has not been sufficient to stabilise the price amid these challenges.

In summary, SPARC’s recent price decline is driven by a combination of poor long-term growth, weak profitability, high debt servicing costs, and disappointing quarterly results. The stock’s technical indicators and reduced investor interest further reinforce the bearish outlook, making it a challenging proposition for investors seeking stability and growth in the pharmaceutical research sector.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →